Join collection
Hello, welcome to our official website!
2018(第二十届)中国风险投资论坛于深圳召开
2019-01-12

  -暨首届“成思危奖.风险投资研究贡献奖”颁奖典礼举行

  

  深圳2018年5月23日电 /美通社/ -- 2018年6月8日-10日,“2018(第二十届)中国风险投资论坛”将在深圳五洲宾馆隆重召开。本届论坛由民建中央、广东省人民政府、深圳市人民政府、广州市人民政府共同主办;科学技术部、中国证券监督管理委员会支持。

  

  论坛新闻发布会于5月22日下午在深圳五洲宾馆召开,民建中央、广东省金融办、深圳市金融办、广州市金融局、中国科学院大学教育基金会成思危基金、深圳市宝安区人民政府、中国风险投资研究院、中国证券基金业协会、广州市科创委、深圳市科创委等主承办单位的领导出席了新闻发布会,民建中央调研部研究室主任王虎主持新闻发布会并代表论坛主办单位发言,中国风险投资论坛(CVCF)执行秘书长、中国风险投资研究院院长丁继红代表论坛组委会向媒体介绍了论坛的整体情况,各主承办领导回答了记者的提问。

  

  本届论坛以“新时代、新征程:资本引擎助推全球经济创新升级”为主题,特设主旨演讲、主题演讲、高层论坛、13场主题论坛、2 项专项活动等近30场高层次的交流活动,届时将有1000+风险投资大咖,国家及地方政府引导基金负责人,上市公司总裁,独角兽企业/类独角兽企业创始人,200+中央及地方政策制定者、经济学家,及主流财经记者出席盛会,这将是一次风险投资界各方思想碰撞与交融的盛典,也将是一次资本的全球汇聚!

  

  群雄齐聚,论道风投新未来

  

  本届论坛将有各主办方领导发表重要讲话。此外,深圳证券交易所党委副书记、总经理王建军,中国证券投资基金业协会党委书记、会长洪磊,美国哈佛大学商学院终身教授Josh Lerner、中国保险学会党委书记、会长姚庆海,联想集团有限公司董事局名誉主席、联想集团**顾问柳传志,中银国际控股有限公司**执行官兼执行总裁李彤,香港交易所董事总经理、**中国经济学家巴曙松,前海母基金**执行合伙人靳海涛,等近百位行业领军人物也将在本届论坛上建言献策,共谋中国风险投资行业新未来。

  

  2018中国首届未来独角兽大赛(深圳站)震撼来袭

  

  深圳市宝安区人民政府、中国风险投资研究院、共青团中央中国青年创业就业基金会、南沙股权投资基金管理有限公司共同主办的“2018中国首届未来独角兽大赛(深圳站)”震撼来袭, 1000+参选企业、200+投资机构、120+知名媒体慕名而来。大赛现场,50+优质项目***PK、行业顶尖投资人激情点评,有温度的项目预见有态度的投资人,点燃永不熄灭的创业火种,助推潜质独角兽企业成长为真正的独角兽,为中国独角兽企业发展蓄力。

  

  **LP&GP甜蜜约会

  

  特设LP&GP闭门圆桌会议、LP&GP高端交流午宴,知名FOF负责人、国家及各省市政府引导基金主管领导、知名VC/PE机构合伙人欢聚一堂,五小时不间断畅聊市场化母基金、政府引导基金等热门话题,成就一场LP&GP甜蜜约会,引爆资本发展无限可能。

  

  一策两奖齐发布

  

  据深圳市宝安区政府副区长、党组成员高志远介绍,本次宝安区将联合承办2018第二十届中国风险投资论坛,并在本届论坛上对**出台的1+5+6政策文件进行发布。同时,在6月9日上午的LP&GP高端会议上,还将举行宝安区与顶尖金融机构的战略合作签约仪式,以及宝安区产业投资引导基金与招商资本、IDG等顶尖风投机构的签约仪式。

  

  成思危基金理事长成卓女士在发布会上介绍,首届“成思危奖.风险投资研究贡献奖”颁奖典礼将在本届论坛上举行。此奖是奖励国内、国外对风险投资理论研究和对中国的风险投资事业有推动作用的优秀成果,意在推动中国风险投资研究为政府政策法规、引导基金的策略优化提供理论依据,提高在国际理论界的地位,同时促进国际学者对中国风险投资的深入研究。成思危基金是支持教育科研与新经济、管理、现代金融等创新研究与政策推动的公益基金。今后年度还拟对中国现代金融、资本市场和国际金融治理等领域研究作出突出贡献的国内外学者颁奖。

  

  为表彰对风险投资行业做出**贡献,对行业具有重大影响甚至改变行业格局的投资机构和投资人,助推全球风投行业以及创新经济发展,中国风险投资研究院将发布 “CVCRI·2018金投奖”榜单,从2005年起至今评选已超过13年,得到了业界机构及投资人的大力支持与肯定。届时, 16个榜单、近400个获奖单位及个人将现场揭晓。

  

  奋进二十载,情系深圳

  

  2018年是论坛具有里程碑意义的二十周年。砥砺奋进20年,“中国风险投资论坛(CVCF)”已经成为风险投资行业顶尖国际论坛,从2004年正式落户深圳开始,在深圳深耕细作十四年,推动深圳成为全国“风险投资之都”和“科技创新之都”,是构成深圳市作为“国际化金融创新中心”的核心要素。雄关漫道真如铁,而今迈步从头越。2018年,中国风险投资论坛将在新的起点上,携手深圳,共谱风险投资新华章。


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online